Magnetic Resonance Imaging + Biospecimen Collection + Lumbar Puncture + Radiation Therapy + Dabrafenib Mesylate + TRAMETINIB DIMETHYL SULFOXIDE for glioblastoma

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 18 Apr 2019: Trial registered, NCT03919071
  2. 20 Feb 2020: Trial started, NCT03919071

The trials

NCT03919071: Dabrafenib Combined With Trametinib After Radiation Therapy in Treating Patients With Newly-Diagnosed High-Grade Glioma

State
Under way
Phase
Phase 2
People
58 planned
Started
20 Feb 2020
Primary completion
30 Sep 2027
Arms
Treatment (radiation therapy, dabrafenib, trametinib)
Results
None posted
  1. 18 Apr 2019: Trial registered
  2. 20 Feb 2020: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.